Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 35

1.

HIF-1α and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress.

Coudre C, Alani J, Ritchie W, Marsaud V, Sola B, Cahu J.

Cell Cycle. 2016 Jun 24:0. [Epub ahead of print]

PMID:
27340936
2.

Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.

Jardin F, Pujals A, Pelletier L, Bohers E, Camus V, Mareschal S, Dubois S, Sola B, Ochmann M, Lemonnier F, Viailly PJ, Bertrand P, Maingonnat C, Traverse-Glehen A, Gaulard P, Damotte D, Delarue R, Haioun C, Argueta C, Landesman Y, Salles G, Jais JP, Figeac M, Copie-Bergman C, Molina TJ, Picquenot JM, Cornic M, Fest T, Milpied N, Lemasle E, Stamatoullas A, Moeller P, Dyer MJ, Sundstrom C, Bastard C, Tilly H, Leroy K.

Am J Hematol. 2016 Jun 16. doi: 10.1002/ajh.24451. [Epub ahead of print]

PMID:
27312795
3.

Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.

Bustany S, Bourgeais J, Tchakarska G, Body S, Hérault O, Gouilleux F, Sola B.

Oncotarget. 2016 Jun 7. doi: 10.18632/oncotarget.9901. [Epub ahead of print]

4.

Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis.

Bustany S, Cahu J, Descamps G, Pellat-Deceunynck C, Sola B.

J Hematol Oncol. 2015 Apr 23;8:40. doi: 10.1186/s13045-015-0135-3.

5.

Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathway.

Bustany S, Cahu J, Guardiola P, Sola B.

BMC Cancer. 2015 Apr 11;15:262. doi: 10.1186/s12885-015-1240-y.

6.

[Emergence of cancer stem cells or tumor-initiating/propagating cells and relapse in multiple myeloma].

Cahu J, Sola B.

Bull Cancer. 2014 Dec;101(12):1074-9. doi: 10.1684/bdc.2014.2027. Review. French. No abstract available.

PMID:
25467977
7.

Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.

Gaudichon J, Milano F, Cahu J, DaCosta L, Martens AC, Renoir JM, Sola B.

PLoS One. 2014 Sep 25;9(9):e107009. doi: 10.1371/journal.pone.0107009. eCollection 2014.

8.

Expression and subcellular localization of cyclin-dependent kinase inhibitor p27 does not correlate with proliferation pattern of mantle lymphoma cells.

Bustany S, Cahu J, Moros A, Troussard X, Gaël R, Sola B.

Leuk Lymphoma. 2014 Sep;55(9):2204-6. doi: 10.3109/10428194.2013.871633. Epub 2014 Feb 6. No abstract available.

PMID:
24354680
9.

Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.

Moros A, Bustany S, Cahu J, Saborit-Villarroya I, Martínez A, Colomer D, Sola B, Roué G.

Clin Cancer Res. 2014 Jan 15;20(2):393-403. doi: 10.1158/1078-0432.CCR-13-1569. Epub 2013 Oct 31.

10.

Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism.

Sola B, Poirot M, de Medina P, Bustany S, Marsaud V, Silvente-Poirot S, Renoir JM.

Oncotarget. 2013 Jun;4(6):911-22.

11.

A sensitive method to quantify senescent cancer cells.

Cahu J, Sola B.

J Vis Exp. 2013 Aug 2;(78). doi: 10.3791/50494.

12.

4-Hydroxy-tamoxifen-loaded liposomes have potent anti-myeloma activity.

Urbinati G, Marsaud V, Renoir JM, Sola B.

Leuk Lymphoma. 2013 Aug;54(8):1808-10. doi: 10.3109/10428194.2012.757764. Epub 2013 Jan 8. No abstract available.

PMID:
23228023
13.

Cyclin D1 inhibits mitochondrial activity in B cells.

Tchakarska G, Roussel M, Troussard X, Sola B.

Cancer Res. 2011 Mar 1;71(5):1690-9. doi: 10.1158/0008-5472.CAN-10-2564. Epub 2011 Feb 22.

14.

Cyclin D1 regulates p27(Kip1) stability in B cells.

Bustany S, Tchakarska G, Sola B.

Cell Signal. 2011 Jan;23(1):171-9. doi: 10.1016/j.cellsig.2010.09.001. Epub 2010 Sep 15.

PMID:
20837141
15.

Cyclin K and cyclin D1b are oncogenic in myeloma cells.

Marsaud V, Tchakarska G, Andrieux G, Liu JM, Dembele D, Jost B, Wdzieczak-Bakala J, Renoir JM, Sola B.

Mol Cancer. 2010 May 10;9:103. doi: 10.1186/1476-4598-9-103.

16.

Reduction of cell proliferation and potentiation of Fas-induced apoptosis by the selective kappa-opioid receptor agonist U50 488 in the multiple myeloma LP-1 cells.

Kerros C, Brood I, Sola B, Jauzac P, Allouche S.

J Neuroimmunol. 2010 Mar 30;220(1-2):69-78. doi: 10.1016/j.jneuroim.2010.01.010. Epub 2010 Feb 16.

PMID:
20163878
17.

Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model.

Urbinati G, Audisio D, Marsaud V, Plassat V, Arpicco S, Sola B, Fattal E, Renoir JM.

Pharm Res. 2010 Feb;27(2):327-39. doi: 10.1007/s11095-009-0023-z. Epub 2009 Dec 23.

PMID:
20033476
18.

The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies.

Tchakarska G, Le Lan-Leguen A, Roth L, Sola B.

Haematologica. 2009 Dec;94(12):1781-2. doi: 10.3324/haematol.2009.011460. Epub 2009 Aug 13. No abstract available.

19.

Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Kerros C, Cavey T, Sola B, Jauzac P, Allouche S.

J Exp Clin Cancer Res. 2009 Jun 7;28:77. doi: 10.1186/1756-9966-28-77.

20.

Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells.

Renoir JM, Bouclier C, Seguin A, Marsaud V, Sola B.

J Mol Endocrinol. 2008 Mar;40(3):101-12. doi: 10.1677/JME-07-0143. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk